National

After Serum Institute's Covishield, expert panel approves Bharat Biotech's Covaxin

An expert panel of India's central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed COVID-19 vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford COVID-19 vaccine, sources said.

migrator

New Delhi

Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts and analysis subsequent to Friday's review meeting, a source said.

Bharat Biotech had applied to the Drugs Controller General Of India (DCGI) seeking emergency use authorisation for its Covaxin on December 7.

On Friday, the SEC had recommended granting permission for restricted emergency use of Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Also Read

TN Labour Minister Mohamed Farvas assures no recurrence of Tiruvallur-like industrial accidents

Inflow to Bhavanisagar dam drops to 76 cusecs; water levels fall across Erode dams

Keir Starmer resigns as UK PM, sets out timetable for new leader

Offloaded passengers left in limbo at Chennai Airport

Allahabad HC declines out-of-turn hearing on plea seeking probe into Ram Temple offerings row